Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Potential approval of quizartinib in AML & its place in the AML treatment regimen

Mark Levis • 21 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia Midostaurin Quizartinib

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly talks on the expected approval of quizartinib in acute myeloid leukemia (AML), commenting on where it might fit in the treatment regimen of AML. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals